Skip to main content
Eterna Therapeutics Logo
  • Overview
    • News
    • Events & Presentations
    • Stock Information
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
    • Financials
      • Form 8937
      • SEC Filings
    • Governance
      • Corporate Governance
      • Management Team
    • Resources
      • Information Request Form
      • Investor Email Alerts
Site Search
  • Overview
    • News
    • Events & Presentations
    • Stock Information
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
    • Financials
      • Form 8937
      • SEC Filings
    • Governance
      • Corporate Governance
      • Management Team
    • Resources
      • Information Request Form
      • Investor Email Alerts

News

  • Overview
    • News
    • Events & Presentations
    • Stock Information
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
    • Financials
      • Form 8937
      • SEC Filings
    • Governance
      • Corporate Governance
      • Management Team
    • Resources
      • Information Request Form
      • Investor Email Alerts
Normal
Press release year list 2023 2022 2021 2020 2019 2018
03/20/2023
Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights
02/22/2023
Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications
01/04/2023
Eterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and President

Contact Us

investors@eternatx.com

Shareholder Services:

Website:
www.computershare.com

Phone:
1 (800) 736-3001 (U.S.)
1 (781) 575-3100 (non-U.S.)

Email:
web.queries@computershare.com

Regular Mail:
Computershare
P.O. Box 43006
Providence RI, 02940-3006

Courier Delivery:
Computershare
150 Royall St., Suite 101
Canton, MA 02021

Quick Links

  • SEC Filings
  • Information Request Form

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Eterna Therapeutics, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Eterna Therapeutics to send you the requested Investor Email Alert updates.

* Required

*
*





Unsubscribe

Email Alert Sign Up Confirmation

Eterna Therapeutics Logo
© Eterna Therapeutics - All rights reserved
Powered By Q4 Inc. 5.90.0.6 (opens in new window)